DBV Technologies S.A.
DBVT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001613780
No open-market purchases or sales by DBV Technologies S.A. insiders were filed in the last 90 days; 80 institutions reported holding it in 13F filings for Q2 2026, worth $345.9M in total; Duquesne Family Office is the only superinvestor holding it.
Other share classesDBVTF
Key figures
- Market capADS ratio not in SEC data
- –
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +7 vs. previous quarter
- 80
- 13F valueReported value at the end of Q2 2026
- $345.9M
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $5.64M
- +35.8% year over year
- Net income, FY2025
- -$146.9M
- −229.0% year over year
- Free cash flow, FY2025
- -$121.7M
- No comparable prior period
- Revenue, Q3 FY2026
- $1.60M
- −42.3% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $146.9M (2607.3% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 806.7K
- Shares sold short
- Change
- −65.4K
- −7.5% vs. previous
- Days to cover
- 1.67
- At average daily volume
Superinvestors holding DBVT, Q2 2026
Go to the superinvestors tab1 superinvestor reports holding DBV Technologies S.A. on Form 13F. Percentages are the stock's share of each portfolio.
Duquesne Family Office
Stanley Druckenmiller
0.1%
DBV Technologies S.A.'s share of the portfolio
- Shares
- 383,363
- Value
- $6.29M
Latest insider trades
See all insider tradesOpen-market purchases and sales by DBV Technologies S.A. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 31, 2026 (view filing)4:15 PM ET | Jul 29 | 2 days | Mohideen PharisChief Medical Officer | SSale | −464 | $2.70 | −$1.25K | −0.3%144.5K after | |
| Feb 2, 2026 (view filing) | Jan 29 | 4 days | Mohideen PharisChief Medical Officer | SSale | −534 | $4.86 | −$2.60K | −0.4%145.0K after | |
| Dec 19, 2025 (view filing)4:04 PM ET | Dec 17-18 | 2 days | Caisse Des Depots Et Consignations and 4 othersOther: Member of 10% owner group | SSale | −3.37M | $4.60 | −$15.5M | −31.6%7.30M after | 3 lots |
| Nov 25, 2025 (view filing) | Nov 20-21 | 5 daysLate | Mohideen PharisChief Medical Officer | SSale | −8.12K | $2.86 | −$23.2K | −7.4%101.5K after | 2 lots |
| Jul 31, 2025 (view filing) | Jul 29 | 2 days | Mohideen PharisChief Medical Officer | SSale | −464 | $2.22 | −$1.03K | −0.4%109.6K after | |
| May 27, 2025 (view filing) | May 22 | 5 days | Mohideen PharisChief Medical Officer | SSale | −397 | $1.84 | −$730.48 | −0.4%110.1K after | |
| Jan 31, 2025 (view filing) | Jan 30 | 1 day | Mohideen PharisChief Medical Officer | SSale | −600 | $0.85 | −$510 | −0.5%110.5K after | |
| Nov 27, 2024 (view filing) | Nov 22-25 | 5 daysLate | Mohideen PharisChief Medical Officer | SSale | −907 | $0.5549 | −$503.31 | −0.8%111.1K after | 2 lots |
| Nov 25, 2024 (view filing) | Nov 21 | 4 days | Mohideen PharisChief Medical Officer | SSale | −2.35K | $0.54 | −$1.27K | −2.1%112.0K after | |
| Jul 31, 2024 (view filing) | Jul 29 | 2 days | Mohideen PharisChief Medical Officer | SSale | −1.78K | $0.98 | −$1.75K | −2.2%79.4K after |
Top 10 13F holders, Q2 2026
See all 80 holdersThe largest institutional positions in DBV Technologies S.A. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| MPM Oncology Impact Management LP | 3,666,284 | $60.1M | 3.67% | −1,547,077−29.7% | Reduced |
| Siren, L.L.C. | 1,857,362 | $30.5M | 0.62% | 00.0% | Unchanged |
| Vivo Capital, LLC | 1,844,758 | $30.3M | 2.76% | −822,811−30.8% | Reduced |
| Perceptive Advisors LLC | 1,653,350 | $27.1M | 0.42% | +688,959+71.4% | Added |
| Baker Bros. Advisors LP | 1,461,425 | $24.0M | 0.12% | 00.0% | Unchanged |
| Artisan Partners Limited Partnership | 1,372,851 | $22.5M | 0.04% | −846,535−38.1% | Reduced |
| UBS Group AG | 1,313,439 | $21.5M | 0.00% | +1,233,902+1,551.4% | Added |
| Morgan Stanley | 954,908 | $15.7M | 0.00% | +808,792+553.5% | Added |
| Logos Global Management LP | 915,000 | $15.0M | 0.65% | +915,000 | New |
| Patient Square Capital LP | 909,474 | $14.9M | 2.31% | +215,940+31.1% | Added |
Holders of 5% or more of DBVT
See all 7 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of DBV Technologies S.A..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 13D/A | 9.99%25.6M shares | −7.11 ppfrom 17.10% | Jun 13, 20223 filings | Jan 14, 2026 | SEC |
| Suvretta Capital Management, LLC | 13G | 9.90%15.2M shares | New | Apr 11, 20251 filing | Apr 11, 2025 | SEC |
| Janus Henderson Group PLC | 13G/A | 8.80%20.5M shares | +6.20 ppfrom 2.60% | Dec 8, 20253 filings | Jan 8, 2026 | SEC |
| Invus Global Management, LLC | 13G/A | 7.90%24.7M shares | +1.40 ppfrom 6.50% | Oct 14, 20254 filings | Nov 12, 2026 | SEC |
| Adage Capital Management, L.P. | 13G/A | 7.31%22.3M shares | −2.68 ppfrom 9.99% | Aug 12, 20252 filings | May 13, 2026 | SEC |